August 25, 2021 7:40am

The Biostage (BSTG) Chronicles: BSTG again, expended some serious dollars to buy more another 10,590 shares (+$0.16 to $2.05) after Monday’s purchase of 38,354 shares (+$0.68 to $1.89) traded, after months of 100 to 1,100 daily trading volume. Is it all about exercising $2.00 warrants from multiple private placements to raise any cash for a clinical trial (with an IND aged by 1.5 years) that never began or ever will?

WHERE is the SEC?

 

Pre-open indications: SELLs: 4; BUYs: 2; Maintain SELL: 1

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing!

What I provide is a trusted source of share pricing intelligence

Dow futures are DOWN -0.01% (-4 points), S&P futures are DOWN -0.04% (-2 point) and NASDAQ futures are DOWN -0.07% (-10 points)

 

U.S. stock index futures crawling to a down or flat open on Wednesday

European markets were subdued

Asia-Pacific markets were likewise subdued

 

Henry’omics:

Global markets are waiting for “our” Fed to speak … tomorrow and Friday.

Investors are eyeing the Federal Reserve’s annual central banking event in Jackson Hole, Wyo. later this week, focused on whether or not central bankers will detail their plans for tapering monetary stimulus. The Fed has started discussions to pull back its $120 billion a month bond-buying program by the end of this year. <CNBC>

It is said that, “Markets have been boosted by signs that delta variant cases could be peaking I don’t see or hear it?

Taper talk is the worry, but if inflation continues to run hot and economic data continues to be mixed the timing of tapering could get pushed,” noted Lindsey Bell, chief investment strategist at Ally Invest. “It’s unlikely that the Fed will force a taper on an economy that isn’t ready, and the outlook is becoming less certain with the rise of the Delta variant.” <CNBC>

 

If you didn’t know what happen at Friday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

 

  • The Nasdaq closed UP +77.15 points (+0.52%);
  • The IBB closed down -0.28% and XBI closed up +0.01%;
  • Sector volume was LOW with 3 of the 21-upside having higher than the 3-month average volume with very LOW volume of 1 of 12-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +0.07 points or +0.41% at 17.22;
  • Tuesday’s percentage (%) of the 21-upside were +0.38% (VCEL) to +9.21% (BLCM) while the 12-downside -0.41% (RGNX) to -3.95% (PGEN);

 

  • Q3/21: August: 9 positive and 8 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

Q2/21:

  • June: 15 positive and 8 negative closes
  • May:  8 positive, 12 negative closes and 1 holiday
  • April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with the “pump/promote”?

Biostage (BSTG) closed up again +$0.28 with 10,590 shares traded after Monday’s +$0.68 to $1.89 with 38,354 shares traded, Friday’s -$0.07 to $1.21 with 570 shares traded, Thursday’s flat with 50 shares traded and last Wednesday’s -$0.10 with 739 shares traded.

Question#1: HOW did “this” all get started … is it related to past … VISAS which included INVESTMENT to get Chinese communist leaders and executive’s children into American schools and universities?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

Pre-open Indications:

BUY:

BioLife Solutions (BLFS) closed down -$0.27 and has a positive +$5.01 or +10.78% pre-market indication;

Regenxbio (RGNX) closed down -$0.31 and has a positive +$1.91 or +6.04% aftermarket indication;

 

SELL:

CRISPR Therapeutics (CRSP) closed up +$1.44 and has a negative -$0.46 or -0.36% pre-market indication;

Intellia therapeutics (NTLA) closed up +$4.26 and has a negative -$2.23 or -1.37% pre-market indication;

Pluristem (PSTI) closed up +$0.05 and has a negative -$0.01 or -o,33% pre-market indication;

Editas Medicine (EDIT) closed down -0.64 and has a negative -$0.21 or -0.32% pre-market indication,

 

 

The BOTTOM LINE: August is a historically volatile month for markets and this year is no different, with investors currently climbing multiple walls of worries …

The alternating cycle of being oversold is the ability to be overbought after multiple sessions and the … REVERT back.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

Investors should take short-term profits to cash-up for coming drifts!

Some earnings’ Reports Outstanding:

  • Applied Genetic Technologies (AGTC), Mesoblast (MESO), Pluristem (PSTI) and Pluristem (PSTI), ReNeuron (RENE.L)

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.